Abiopharma

🔍 Buczkowski Michelle (Executive)

Company: Eos Energy Enterprises, Inc. (EOSE)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Acquired 22,938 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 70,711.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 11,469 shares of Common Stock at $5.87 per share (Direct)
  Date: 2026-06-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 59,242.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 22,938 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,876.00 | transaction_form_type: 4 | Footnotes: F4, F1, F5, F5

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
• F2: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025 to cover estimated tax withholding obligations in connection with the vesting of restricted stock units.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $6.15, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
• F4: The reporting person received a grant of RSUs under the Issuer's 2020 Incentive Plan, which will vest in three equal installments on each of the first three anniversaries of the grant date, subject to continued service through each vesting date.
• F5: Not applicable.